Gregory Kricorian

2.2k total citations · 1 hit paper
23 papers, 1.7k citations indexed

About

Gregory Kricorian is a scholar working on Immunology, Dermatology and Rheumatology. According to data from OpenAlex, Gregory Kricorian has authored 23 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Immunology, 11 papers in Dermatology and 9 papers in Rheumatology. Recurrent topics in Gregory Kricorian's work include Psoriasis: Treatment and Pathogenesis (18 papers), Dermatology and Skin Diseases (11 papers) and Autoimmune and Inflammatory Disorders Research (8 papers). Gregory Kricorian is often cited by papers focused on Psoriasis: Treatment and Pathogenesis (18 papers), Dermatology and Skin Diseases (11 papers) and Autoimmune and Inflammatory Disorders Research (8 papers). Gregory Kricorian collaborates with scholars based in United States, Canada and United Kingdom. Gregory Kricorian's co-authors include James G. Krueger, Chris B. Russell, Alan Menter, Girish Aras, Craig L. Leonardi, Juan Li, Jean‐Paul Ortonne, Scott Baumgartner, Elizabeth H. Thompson and Kim Papp and has published in prestigious journals such as New England Journal of Medicine, Journal of Investigative Dermatology and Journal of the American Academy of Dermatology.

In The Last Decade

Gregory Kricorian

23 papers receiving 1.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Brodalumab, an Anti–Interleukin-17–Receptor Antibody for Psoriasis

2012 729 citations Kim Papp, Craig L. Leonardi et al. New England Journal of Medicine profile →

Peers

Countries citing papers authored by Gregory Kricorian

Since Specialization

Citations

This map shows the geographic impact of Gregory Kricorian's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gregory Kricorian with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gregory Kricorian more than expected).

Fields of papers citing papers by Gregory Kricorian

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gregory Kricorian. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gregory Kricorian. The network helps show where Gregory Kricorian may publish in the future.

Co-authorship network of co-authors of Gregory Kricorian

This figure shows the co-authorship network connecting the top 25 collaborators of Gregory Kricorian. A scholar is included among the top collaborators of Gregory Kricorian based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gregory Kricorian. Gregory Kricorian is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Treatment patterns and clinical outcomes in patients with rheumatoid arthritis initiating etanercept, adalimumab, or Janus kinase inhibitor as first-line therapy: results from the real-world CorEvitas RA Registry 2023 ·Arthritis Research & Therapy ·Dimitrios A. Pappas, Jacqueline O’Brien, Lin Guo, Ying Shan, Joshua F. Baker, Gregory Kricorian, Scott Stryker, David H. Collier	7
2	Real‐World Evidence Assessing Psoriatic Arthritis by Disease Domain: An Evaluation of the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry 2023 ·ACR Open Rheumatology ·Philip J. Mease, Jacqueline O’Brien, (unknown), Gregory Kricorian, Scott Stryker, David H. Collier, Alexis Ogdie	3
3	Impact of clinical domains other than arthritis on composite outcomes in psoriatic arthritis: comparison of treatment effects in the SEAM-PsA trial 2022 ·RMD Open ·Philip Helliwell, Phillip J. Mease, Arthur Kavanaugh, Laura C. Coates, Alexis Ogdie, Atul Deodhar, Vibeke Strand, Gregory Kricorian, (unknown), David H. Collier, Dafna D. Gladman	4
4	Patient-Reported Nausea and Fatigue Related to Methotrexate: A Prospective, Self-Controlled Study in the ArthritisPower® Registry 2021 ·Rheumatology and Therapy ·W. Benjamin Nowell, (unknown), Kelly Gavigan, (unknown), Hong Zhao, Lang Chen, Scott Stryker, Huifeng Yun, Shilpa Venkatachalam, Gregory Kricorian, Fenglong Xie, Jeffrey R. Curtis	17
5	Performance of composite measures used in a trial of etanercept and methotrexate as monotherapy or in combination in psoriatic arthritis 2020 ·Lara D. Veeken ·Laura C. Coates, Joseph F. Merola, Philip J. Mease, Alexis Ogdie, Dafna D. Gladman, Vibeke Strand, Leonieke van Mens, (unknown), Priscilla K. Yen, David H. Collier, Gregory Kricorian, James Chung, Philip Helliwell	11
6	A retrospective cohort study to evaluate the development of comorbidities, including psychiatric comorbidities, among a pediatric psoriasis population 2019 ·Pediatric Dermatology ·Amy S. Paller, (unknown), Neil A. Accortt, Gregory Kricorian	28
7	Etanercept and Methotrexate as Monotherapy or in Combination for Psoriatic Arthritis: Primary Results From a Randomized, Controlled Phase III Trial 2019 ·Arthritis & Rheumatology ·Philip J. Mease, Dafna D. Gladman, David H. Collier, Christopher T. Ritchlin, Philip Helliwell, (unknown), Gregory Kricorian, James Chung	148
8	Open-Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Failed Therapy With Apremilast. 2018 ·PubMed ·Jerry Bagel, (unknown), Bradley S. Stolshek, Girish Aras, James Chung, Gregory Kricorian, Leon Kircik	5
9	Measurement Properties of the Psoriasis Symptom Inventory Electronic Daily Diary in Patients with Moderate to Severe Plaque Psoriasis 2017 ·Value in Health ·Hema N. Viswanathan, Alex Mutebi, Cassandra E. Milmont, Kenneth B. Gordon, Hilary Wilson, Hao Zhang, Paul Klekotka, Dennis A. Revicki, Matthias Augustin, Gregory Kricorian, Ajay Nirula, Bruce Strober	6
10	OBSERVE-5: Observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results 2014 ·Journal of the American Academy of Dermatology ·Alexa B. Kimball, Kenneth J. Rothman, Gregory Kricorian, David M. Pariser, Paul S. Yamauchi, Alan Menter, Craig Teller, Girish Aras, Neil A. Accortt, Michele Hooper, Kara Rice, Joel M. Gelfand	51
11	OBSERVE-5 interim analysis: An observational postmarketing safety registry of etanercept for the treatment of psoriasis 2013 ·Journal of the American Academy of Dermatology ·Alexa B. Kimball, David M. Pariser, Paul S. Yamauchi, Alan Menter, Craig Teller, Yifei Shi, Mellissa Yong, Kara Creamer, Michele Hooper, Girish Aras, Gregory Kricorian, Joel M. Gelfand	31
12	Validation of the Psoriasis Symptom Inventory (PSI), a patient-reported outcome measure to assess psoriasis symptom severity 2012 ·Journal of Dermatological Treatment ·Donald M. Bushnell, Mona L. Martin, Kelly P. McCarrier, Kenneth B. Gordon, Chiun‐Fang Chiou, Xingyue Huang, Brian G. Ortmeier, Gregory Kricorian	50
13	Brodalumab, an Anti–Interleukin-17–Receptor Antibody for Psoriasis breakdown → 2012 ·New England Journal of Medicine ·Kim Papp, Craig L. Leonardi, Alan Menter, Jean‐Paul Ortonne, James G. Krueger, Gregory Kricorian, Girish Aras, Juan Li, Chris B. Russell, Elizabeth H. Thompson, Scott Baumgartner	729
14	The Emerging Role of IL-17 in the Pathogenesis of Psoriasis: Preclinical and Clinical Findings 2012 ·Journal of Investigative Dermatology ·Roland Martinꝉ, Jennifer E. Towne, Gregory Kricorian, Paul Klekotka, Jóhann E. Guðjónsson, James G. Krueger, Chris B. Russell	351
15	Early development and qualitative evidence of content validity for the Psoriasis Symptom Inventory (PSI), a patient-reported outcome measure of psoriasis symptom severity 2012 ·Journal of Dermatological Treatment ·Mona L. Martin, Kelly P. McCarrier, Chiun‐Fang Chiou, Kenneth B. Gordon, Alexa B. Kimball, Abby S. Van Voorhees, Alice B. Gottlieb, Xingyue Huang, Denise Globe, (unknown), Hema N. Viswanathan, Gregory Kricorian	33
16	Moderate to severe plaque psoriasis with scalp involvement: A randomized, double-blind, placebo-controlled study of etanercept 2011 ·Journal of the American Academy of Dermatology ·Jerry Bagel, Charles Lynde, Stephen K. Tyring, Gregory Kricorian, Yifei Shi, Paul Klekotka	88
17	Intermittent etanercept therapy in pediatric patients with psoriasis 2010 ·Journal of the American Academy of Dermatology ·Elaine C. Siegfried, Lawrence F. Eichenfield, Amy S. Paller, David M. Pariser, Kara Creamer, Gregory Kricorian	40
18	Efficacy and safety of etanercept in children and adolescents aged≥8 years with severe plaque psoriasis 2010 ·European Journal of Dermatology ·Ian Landells, Amy S. Paller, David M. Pariser, Gregory Kricorian, (unknown), C. Molta, Bruce Freundlich	18
19	OBSERVE-5, an Observational Post-Marketing Safety Surveillance Registry of Etanercept for the Treatment of Psoriasis: A Model for Studying New Psoriasis Therapies 2010 ·Alexa B. Kimball, David M. Pariser, Paul S. Yamauchi, Alan Menter, Craig Teller, Yifei Shi, Kara Creamer, Peter McCroskery, Gregory Kricorian, Joel M. Gelfand	4
20	Dermatofibrosarcoma Protuberans Growing Around Plantar Aponeurosis: Excision by Mohs Micrographic Surgery 2000 ·Dermatologic Surgery ·Gregory Kricorian, Carl F. Schanbacher, Paul Kelly, Richard G. Bennett	14

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact